Motavizumab

According to the lawsuit, filed Aug. 21 in U.S. District Court, Abbott had a deal to develop and market a new drug called motavizumab in countries outside the U.S. The drug was to be a successor to an earlier respiratory drug developed by Gaithersburg-based MedImmune called Synagis which has millions of dollars in sales in the U.S. alone.

halted further development in December of its next-generation vaccine to prevent RSV - a product called motavizumab that was meant to replace its blockbuster-selling Synagis drug. ❋ Unknown (2011)

The discontinuation of motavizumab changes the playing field in this potentially lucrative area, and makes Alnylam Pharmaceuticals Inc. and Cubist Pharmaceuticals Inc.'s ALN-RSV01, currently in Phase II development, the most advanced RSV therapy in de velopment. ❋ Unknown (2011)

AstaZeneca said on Tuesday that it is halting development of its pediatric respiratory drug motavizumab. ❋ MarketNewsVideo.com (2010)

AstraZeneca said it halted the development of the drug motavizumab for the prevention of a respiratory infection, resulting in a $445 million impairment charge in the fourth quarter. ❋ Unknown (2010)

LONDON — AstraZeneca PLC said Tuesday that it has halted the development of the drug motavizumab for the prevention of a respiratory infection, resulting in a $445 million impairment charge in the fourth quarter. ❋ Patricia Kowsmann (2010)

The company said motavizumab remains in development for other respiratory syncytial-virus treatment. ❋ Patricia Kowsmann (2010)

Berenberg Bank analyst Alistair Campbell said motavizumab wasn't "mission critical" for AstraZeneca since MedImmune already made a similar product that is sold as Synagis. ❋ Patricia Kowsmann (2010)

AstaZeneca AZN said today it is halting development of its pediatric respiratory drug motavizumab. ❋ MarketNewsVideo.com (2011)